ATNM stock news · Actinium Pharmaceuticals, Inc.
Get alerts for ATNM
Follow Actinium Pharmaceuticals, Inc. (ATNM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ATNMActinium Pharmaceuticals is giving a new employee a special grant as part of their hiring process.
NeutralActinium announced an inducement grant for a new employee and called it standard procedure. The story reports no change to the company’s outlook.
Actinium Pharmaceuticals' stock is going up on Tuesday after good news about its new treatment.
Good for ATNMATNM reported early ATNM-400 trial findings: the first patients had no dose-stopping problems, and scans showed the drug stayed in tumors. The early evidence is encouraging, but benefit is unproven.
12 health care companies are seeing big changes in their stock prices today.
NeutralThe article reports a rise in Actinium Pharmaceuticals shares but gives no company news explaining it. The share move alone does not change what the article says about the company.
Actinium Pharmaceuticals is changing its leadership, naming Matt David, M.D. as the new Chief Financial Officer.
NeutralActinium named an experienced finance executive as CFO, but the filing also lists pay and stock awards and reports no new company results. The appointment alone does not change the company's outlook.
On Tuesday, 12 health care stocks saw big price changes during the day.
Good for ATNMActinium Pharmaceuticals rose 18.33% to $1.22, showing a positive market move during the session.
Actinium Pharmaceuticals, Inc. faces potential delisting after failing to meet ongoing listing criteria; listing transfer initiated (ATNM).
Good for ATNMActinium Pharmaceuticals has filed a Form 8-K indicating that it has received a notice of delisting due to failure to satisfy continued listing standards. This news is significant as it raises concerns about the company's compliance and future viability in the market, likely leading to a bearish sentiment among investors.